Sukumar Nagendran - 12 Jan 2026 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role
President and Head of R&D, Director
Signature
/s/ Kamran Alam, Attorney-in-Fact
Issuer symbol
TSHA
Transactions as of
12 Jan 2026
Net transactions value
-$712,560
Form type
4
Filing time
14 Jan 2026, 16:45:07 UTC
Previous filing
01 Dec 2025
Next filing
27 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Nagendran Sukumar President and Head of R&D, Director C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS /s/ Kamran Alam, Attorney-in-Fact 14 Jan 2026 0001665124

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TSHA Common Stock Options Exercise $77,804 +111,324 +11% $0.6989 1,117,763 12 Jan 2026 Direct
transaction TSHA Common Stock Options Exercise $151,636 +88,676 +7.9% $1.71 1,206,439 12 Jan 2026 Direct
transaction TSHA Common Stock Sale $942,000 -200,000 -17% $4.71 1,006,439 12 Jan 2026 Direct F1, F2
transaction TSHA Common Stock Award $0 +427,000 +42% $0.000000 1,433,439 12 Jan 2026 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TSHA Employee Stock Option (right to buy) Options Exercise $0 -111,324 -50% $0.000000 111,359 12 Jan 2026 Common Stock 111,324 $0.6989 Direct F4
transaction TSHA Employee Stock Option (right to buy) Options Exercise $0 -88,676 -16% $0.000000 474,941 12 Jan 2026 Common Stock 88,676 $1.71 Direct F5
transaction TSHA Employee Stock Option (right to buy) Award $0 +274,000 $0.000000 274,000 12 Jan 2026 Common Stock 274,000 $4.86 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.565 to $4.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.
F4 The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.
F5 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
F6 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.